May 7, 2020 -- ACON, a leading global medical device manufacturer, announced today the availability of its SARS-COV-2 IgG/IgM Rapid Test. ACON’s test is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG and IgM) to SARS-CoV-2 (COVID-19) in human serum, plasma, or whole blood.

The test is intended as an aid in identifying individuals with an adaptive response to SARS-CoV-2, indicating a recent or earlier infection. The test is for the detection and differentiation of IgM and IgG antibodies.

“ACON has a reputation for developing high quality products and it continues to do so, with the introduction of our latest, CE Marked, lateral flow test for COVID-19” said Jinn-nan Lin, President of ACON, “We are proud to be part of the solution in combatting the worldwide COVID-19 pandemic.”

ACON’s COVID-19 test is CE marked and will be commercialized worldwide, followed by the United States once it receives the Food and Drug Administration (FDA) clearance under the Emergency Use Authorization (EUA).

ACON’s COVID-19 lateral flow immunoassay has a high sensitivity and specificity and is therefore highly reliable. The Rapid Test can be performed using a small amount of serum, plasma or whole blood specimen. Results are available within 15 minutes of testing.

About ACON

ACON is a privately-owned Diagnostics and Medical Device company, which was founded in 1995. ACON produces a broad range of medical diagnostic and healthcare products that are sold in over 130 countries worldwide. The company continues to expand its product lines through extensive research and development, with the goal of helping improve the health and well-being of patients around the world. ACON’s manufacturing facility is a US FDA registered manufacturer of rapid diagnostic and healthcare products. To learn more, please visit www.aconbio.com or contact infomation@aconlab.com.cn.